Cheepsattayakorn graduated Doctor of Medicine from Chiang Mai Medical School, Chiang Mai University, Chiang Mai, Thailand in 1986. He then further had trained in Internal Medicine, Radiology, General Practice, Family Medicine, and Preventive Medicine at Chiang Mai University Medical School. He certified numerous Fellowships from the Royal Col...
Cheepsattayakorn graduated Doctor of Medicine from Chiang Mai Medical School, Chiang Mai University, Chiang Mai, Thailand in 1986. He then further had trained in Internal Medicine, Radiology, General Practice, Family Medicine, and Preventive Medicine at Chiang Mai University Medical School. He certified numerous Fellowships from the Royal Colleges of Physicians of London, Edinburgh and Thailand, Royal College of Physicians and Surgeons of Glasgow, American College of Physicians, and American College of Chest Physicians. Presently, he serves both Editor and Editorial Board Member and also referee of several international journals. He has very high experience in the fields of Pulmonary Diseases and Tuberculosis including Infectious Diseases. He has numerous scientific publications both in national and international journals and books.Recently, he published scientific papers, entitled Parasitic Pneumonia and Lung Involvement , Lung Cancer Chemotherapy, New Treatment and Related Patents, Breath Tests in Respiratory and Critical Care Medicine : From Research to Practice in Current Perspectives, Novel Avian Flu A (H7N9) : Clinical and Epidemiological Aspects, and Management, and Novel Avian Flu A (H7N9) Epidemic : A China's Lesson Learned (Editorial), and textbook chapters, entitled Management of TB in HIV Subjects : The Experience in Thailand, Multidrug-Resistant Tuberculosis-Diagnosis, Treatment, Management, and Control, and Influence of Human Leukocyte Antigen on Susceptibility of Tropical Pulmonary Infectious Diseases. He had been served a Director of the 10th Zonal Tuberculosis and Chest Diseases Center, Chiang Mai, Thailand for a long time and presently serve as Consultant in Respiratory Medicine (Pulmonologist) at the 10th Zonal Tuberculosis and Chest Diseases Center, Chiang Mai, Thailand; Deputy Director and a Senior Expert of the 10th Office of Disease Prevention and Control, Chiang Mai, Thailand, Department of Disease Control, Ministry of Public Health, Thailand.
Novel Therapeutics in Lung Cancer, Nontuberculous mycobacterial infection in HIV- infected patients, Multidrug – resistant tuberculosis patterns in HIV-infected patients, Chemokine gene polymorphisms and their susceptibility to tuberculosis, Breath Tests in Respiratory and Critical Care Medicine, Tropical Infectious Diseases, Human Genetics and Infectious Disease, Environmental and Occupational Pulmonary Diseases
Jocelyn Yelle, M.Sc., Ph.D., is a virologist specialized in Retroviruses and Herpesviruses, with a marked interest in antiviral drug discovery. Born in a small town near Montreal, Canada, he holds an M.Sc. and a Ph.D. degrees in Virology from the Armand-Frappier Institute, a Montreal-based research center modeled on the Pasteur Institute in Paris. During his M.Sc. studies, he investigated the role of endogenous Retroviruses in cell transformation in animal models, while his Ph.D. thesis focused on the ability of certain DNA sequences of human cytomegalovirus to immortalize and transform normal cells into cancer cells. As a postdoctoral fellow at the Clinical Research Institute of Montreal, he explored the ability of tumor suppressor genes to reverse the cancer state in cell culture.
He launched his academic career in the early 1990s, investigating HIV’s ability to establish persistent infections in human cell cultures. He then started collaborating with a chemist colleague, mounting a comprehensive, multidisciplinary research program focusing on small molecules as potential drugs for HIV/AIDS treatment. With his colleague, he later launched Pharmacor Inc., a small biopharmaceutical company, to pursue the same goals. Some of these molecules were eventually acquired by Merck & Co. for further development.
He is Founder and President of Antiviral InteliStrat Inc., a consultancy firm that provides scientific advices, analyses of research projects and counselling, locally and abroad, to biotech/pharma industriesand hospital-based organizations. The firm also owns a proprietary database that contains scientific information on antiviral drugs and vaccines, which can be accessed online upon subscription.
During his career, he has authored or co-authored over 34 peer-reviewed scientific publications and presented his research and results to national and international scientific meetings. His name also appears on 8 U.S. patents related to experimental drugs for HIV/AIDS.
Retroviruses, Herpesviruses, new viruses having the potential to cause pandemics or with high rate of mortality in humans, antiviral drug discovery, novel approaches to prevent or treat viral infections, research on virus-cancer relations
Brian Wigdahl Ph.D is professor and chair of the Department of Microbiology & Immunology, director of the Institute for Molecular Medicine and Infectious Disease, and director of the institute’s Center for Molecular Virology and Translational Neuroscience. The research efforts of the Department and Institute center on the diagnosis, treatment, and prevention of infectious, oncogenic, and inflammatory disease with a cumulative extramural research commitment of just over $60 million.He also serves as the executive director of the interdisciplinary graduate program in molecular medicine. An internationally recognized molecular virologist, He focuses his research on the molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus family. These include the human immunodeficiency virus and the human T cell leukemia virus type 1 (HTLV-1), the first human tumor virus discovered. In particular, efforts are focused on the prevention of HIV sexual transmission and the HIV-induced neurologic complications of HIV/AIDS. He has been funded by the National Institutes of Health for nearly 30 years, with total awards totaling more than $40 million. Current funding includes three NIH R01 research grants and a component of an NIH P30 grant. He is also Co-Director of a Interdisciplinary and Translational Research Training Program in NeuroAIDS designed for graduate students. He current total research commitment is approximately $6 million. He graduated from Augsburg College in Minneapolis and received his doctorate in microbiology from the Medical College of Wisconsin. A senior associate editor of the Journal of NeuroVirology, he also served as chair of the NIH NeuroAIDS and Other End-Organ Diseases Review Committee, served for six years as president of the International Society for NeuroVirology and currently serves as treasurer of the Society. He is the 2013 recipient Pioneer in Neurovirology Award presented in recognition of outstanding individual achievement in the field of neurovirology and awarded by the International Society for NeuroVirology.
Molecular mechanisms, treatment, and prevention of immunologic abnormalities, cancer, and progressive neurologic disorders caused by members of the retrovirus family. These include the human immunodeficiency virus and the human T cell leukemia virus type 1 (HTLV-1), the first human tumor virus discovered. In particular, efforts are focused on the prevention of HIV sexual transmission and the HIV-induced neurologic complications of HIV/AIDS.
W John Martin is Medical Director of the Institute of Progressive Medicine, within MI Hope Inc., a non-profit United States public charity specializing in the study of viruses causing mental illnesses. He received his medical degree from the University of Sydney in 1965 and the PhD degree from the University of Melbourne in 1970. He is Board Certified in both Anatomic and Clinical Pathology with sub specialty qualifications in Immunopathology and in Medical Microbiology. Using molecular assays and specialized virus culture techniques, he pioneered research leading to the detection of stealth adapted viruses. These viruses are derived from conventional viruses but do not normally provoke an inflammatory response. This is because of the deletion or mutation of the major antigens normally targeted by the cellular immune system. The viruses can, nevertheless, be suppressed through an alternative cellular energy (ACE) pathway. Dr. Martin explains the ACE pathway in terms of a natural energy force termed KELEA (kinetic energy limiting electrostatic attraction). He has further shown that water and other materials can capture and transmit KELEA to living organisms, including humans, animals and plants. This has led to a new paradigm of energy based medicine and agriculture. He works in South Pasadena, California, USA.
Virology; Stealth adapted viruses; Herpes viruses; Cytomegalovirus; HIV; Biophysics; Cellular energy; Cellular immunity; Homeopathy; Complimentary and Alternative Medicine; Autism; Mental illnesses; Psychiatry; Neurology; Neuropathology; Water
Peng Yin, M.D., PhD is currently the Director, Global Scientific Affairs, Medical and Scientific Affairs, Diagnostics Research, Abbott. He received his M.D. from Tianjin Medical School, China and worked as a General Surgeon for 5 years; then received his PhD in Molecular Virology from University of Manitoba, Canada and postdoctoral training with Prof. David Knipe at Harvard University, Medical School. Prior joining Abbott, he worked as a Senior Scientist in biotech companies in USA. He has patent, book chapter and publications in Nature publication, Cell and Journal of Virology. He was invited to give speeches in Scientific Symposia around the world, such as Australia NRL Annual Meeting, China National Liver Disease’s Laboratory Diagnosis and Clinics Conference. In addition, he is a honorary Professor, Tianjin Medical University Cardiovascular Institute, TEDA International Cardiovascular Hospital, IFCC Congresses and Conference Executive Committee Member and AACC Chair-elect, Industry Division.
HBV, HCV diagnostics, screening, mutations, therapeutic monitoring, Liver fibrosis and HCC due to viral hepatitis; HIV diagnostics, screening, new emerging HIV variants; HTLV.
Institute of Experimental Medicine AS CR Czech Republic
Josef Bodor completed his PhD from Institute of Molecular Genetics, Prague in the Department of Molecular Oncology. He completed his M. Sc in 1984 from University of J.E. Purkynje, Brno (Czech Rep). He is Senior Investigator, Institute of Experimental Medicine AS CR, v.v.i. EU Center of Excellence. He worked as Visiting Professor, Institute of Immunology, and Universitätmedizin JGU Mainz, Germany. He was Assistant Professor, Columbia University, College of Physicians and Surgeons, Department of Pathology, New York, NY, Assistant Professor of Medicine, Boston University, School of Medicine, Boston, MA. He was Instructor in Medicine at Harvard Medical School, Boston, MA. He has received many Honors and Awards in his career. He has patent rights for his inventions.
Hematopoetic stem cell (HSC), HSC therapy, CCR5D32, human immunodeficiency virus (HIV), graft-versus-host (GvHD) disease, CD4+ T regulatory cells (Tregs), CD4+ T conventional cells (Tcons), interleukin-2 (IL-2), cyclic AMP (cAMP), inducible cAMP early repressor (ICER)
Dr. Robert R. Redfield has been actively engaged in clinical research and clinical care of chronic human viral infections and infectious diseases, especially HIV, for more than 30 years. He served as the founding director of the Department of Retroviral Research within the Military’s HIV Research Program, and retired after 20 years of service in the US Army Medical Corp, when he co‐founded the University of Maryland’s Institute of Human Virology with Dr. William Blattner and Dr. Robert C. Gallo. He is currently a Professor of Medicine, Professor of Microbiology and Immunology, and serves as the IHV Associate Director and Director of the Division of Clinical Care and Research at the Institute of Human Virology, as well as providing leadership as the Chief of Infectious Diseases and Vice Chair of Medicine at the University of Maryland, School of Medicine. Dr. Redfield made several important early contributions to our understanding of HIV, to include the demonstration of the importance of heterosexual transmission and the development of the Walter Reed staging system for HIV infection, and the demonstration of active HIV replication in all stages of HIV infection.
His present research interest is focused on targeting host cell pathways as novel strategies for the treatment and prevention of HIV infection and chronic viral pathogens. In addition, Dr. Redfield oversees an extensive clinical program providing HIV care and treatment to more than 5,000 patients in the Baltimore/Washington DC community. He also leads extensive USG funded global HIV care and treatment programs, and vibrant post‐graduate medical education programs, which are active in 6 African countries and 1 Caribbean country, serving more than 700,000 people living with HIV.
Dr. Redfield has been actively engaged in clinical research and clinical care of chronic human viral infections, especially HIV. His dominant area of research interest is the development of novel biological approaches to the treatment of chronic viral pathogens with a particular focus of targeting host cell pathways for their therapeutic potential. Several novel areas under active translation investigation include: targeting key biochemical pathways of nucleotide biosynthesis to enhance activity of specific antiretroviral medication; targeting cell activation with specific cell cycles as a primary treatment target; use of G1 cell cycle agents to down regulate expression of key HIV host cell receptors; use of G1 cell cycles to enhance antiviral activity of HIV entry inhibitors; and the use of HIV specific proteins as therapeutic vaccines.
Dr. Redfield is also actively involved in clinical research focused on the evaluation of alterative HIV treatment strategies designed to improve treatment outcome and the evaluation of new commercially developed antiviral medications. The clinical research unit which he oversees has more than 30 active intervention trials. Dr. Redfield’s research focus is driven by his goal to develop durable treatment for persons living with HIV infection and other chronic viral infections in the US and throughout the world, including resource-limited settings.
Presently, Dr. Redfield oversees an extensive clinical program providing HIV care and treatment to more than 4,000 patients in the Baltimore-Washington community. He also oversees an extensive care and treatment program as part of the President’s Emergency Plan for AIDS Relief, which is active in 9 countries in Africa and the Caribbean and is now providing ARV treatment to more than 50,000 people living with HIV. Treatment programs outcome improvement is driven by targeted program evaluation and operational research.
Refat Sadeq, from Egypt who has been on microbiology over 37 years. Hehas started and graduated in Zagazig Faculty of Medicine for M.Sc. and Ph.D.,then started to research articles reaching more than 80 articles, many of which have been published in international scientific journals, and he has reviewed over 100 edits on different journal sites. He is a Featured Author, for books in Medical Microbiology and Immunology for both medical students and nurses. He also assisted in building many units in his department but the favorite one was that of Virology and molecular biology. He loves how to help junior doctors in his department tosolve their scientific problems. His advice to new contributors is to take your time to get to know all the tools and to invest your energy and be sure that success will happened.
Virology and molecular biology especially for viral genetics.
Global Health, Health Promotion as well as Health of Immigrants. I hope to be in a position to develop a Health Promotion program for parents and caregivers of HIV positive children to assist them to improve their communication.
Ateef Qureshi was borned in India, migrated to Pakistan with his parents and was raised in Karachi, Pakistan. After obtaining, BSc (Hons) and MSc in Bacteriology from University of Karachi, Pakistan, (placed Second according to merit in both exams) he joined Pakistan Medical Research Center, University of Maryland, International Center for Medical Research and Training , Lahore, Pakistan. There he worked with Rickettsia tsutsugamushi and isolation and characterization of viruses such as Smallpox and Arboviruses.In 1967, he received a teaching fellowship from Brigham Young University, Utah to continue his education working under Dr. Dennis Trent, on biology of St. Louis encephalitis virus, obtaining MS in 1969. As Dr. Trent was moving to University of Texas School of Medicine, he requested Ateef to join him in San Antonio pursuing his doctoral degree under him. There he worked on structural and nonstructural proteins of St. Louis encephalitis, Japanese B encephalitis, West Nile encephalitis and Dengue viruses. These proteins were studied further as specific diagnostic antigens for each of the viruses.
After his PhD, he moved to University of Sherbrooke School of Medicine in Canada to join the polyoma virus group led by Dr. Pierre Bourgaux, as a post-doctoral fellow at NCERC, Canada, followed by a prestigious award from the Cancer Research Society of Canada. Later he was appointed as NCERC Professional assistant at the same lab with Pierre Bourgaux.In 1979 he was appointed assistant Professor at the University of New Brunswick, Canada, where he stayed for 2 years and then moved to Bahrain in the Middle East. There he helped developed the newly established University working with the UNESCO advisors. In 1984 he was seconded to the newly established Arabian Gulf University Medical School , to develop and execute the premedical program for the medical school.He stayed in Bahrain for 12 years until he moved to Grenada, West Indies in 1993. During his tenure at St. Georges University School of Medicine, he have been involved in developing the Medical Microbiology course as course director and was actively involved in developing the graduate program in Microbiology. He had supervised many MSc, PhD and MSc/MD dual degree students.
He had been invited to Pakistan twice, once through the UNDP Transfer of Technology Program to establish and develop the Plant virology diagnostic laboratory for the Agriculture department and second time, by the Higher Education Commission to run workshops of Public Health interest and how to write multiple choice questions. He is also a member of the Global virology Network. He is also appointed to be the Chair of the CARIBBEAN ONE HEALTH ONE MEDICINE INITIATVE in addition to the St. Georges University ONE HEALTH ONE MEDICINE committee responsible to organize International Conferences on One Health theme.
Virus pathogenesis, Viral diagnostics, Water quality in relation to viral pathogens and antigens.
Professor Lynne Webber is the Head of the Department of Medical Virology, Faculty of Health Sciences at the University of Pretoria. She also has a dual appointment with the National Health Laboratory Service (NHLS) that provides diagnostic laboratory services and research opportunities throughout South Africa and Africa. Professor Webber’s Departmental research programmes include the role of blood borne viruses such as HIV, hepatitis B and hepatitis C in occupational exposures, zoonotic and arbovirus surveillance, enteric, food and waterborne viruses of public health importance, human papilloma virus research and the detection of neurotropic virus infections in selected clinical cases. She has research collaboration with the Department of Forensic Medicine, University of Pretoria. She is actively involved with many national and international presentations, lectures and has been a plenary speaker for numerous congresses and scientific meetings. Under- graduate and post- graduate students are mentored, trained and supervised and she is a national examiner for Clinical Virology, South Africa.
The Department of Medical Virology has diverse and exciting research activities and this gives rise to opportunities for academic and scientific endeavors, publications and community outreach events. The Enteric and Environmental Research Group within the Department focuses on the prevalence, detection and molecular epidemiology of enteric viruses that are potentially food- and waterborne.On a personal note, she breeds horses and enjoys amateur astronomy
Blood borne viruses, such as HIV, hepatitis B and hepatitis C
Ilya B Tsyrlov is a native of Russia (1945). He graduated from Novosibirsk University Medical School in 1970 (M.D. diploma with distinction). Received Ph.D. in Biochemistry (1973) and a D. Sci. (Higher doctorate degree) in Biochemistry in 1983. Hold progressively responsible positions in academia, industry and governmental settings: Group Leader (1973-79), Head of Laboratory (1979-87), and then Department of Xeno biochemistry (1987-92) at Russian National Academy of Science. In the US: Senior Scientist at National Cancer Institute, NIH (1991-95); Professor (1995-2010), then visiting associate professor (2010) at Mount Sinai School of Medicine, Department of Medicine. In 2005, He founded and since then has served as Chief Scientific Officer at Xenotox, Inc., an innovation science consulting non-profit company. Has forty years of experience and a world-class reputation in studies on molecular mechanisms of mono oxygenases induction and drug metabolism; site-directed structure modification of analgesics, synthetic opioids, and antimalarials; research decoding mechanisms underlying human virus genome transcriptional activation by the most potent xenobiotic, dioxin. He established and developed Xenobiotical Virology, an interdisciplinary biomedical discipline dealing with mechanisms of potent xenobiotics’ effect on DRE-containing genes of human viruses, and transcription factors and cytokines linked to inflammation and malignancy pathways. Author of 5 monographs and 250+ peer reviewed publications. For the above achievements, several honors and awards were given. In 1993, he was granted permanent residency (followed by US citizenship in 2000) as “scientist of extraordinary abilitiy”.
Molecular mechanisms of mono oxygenases induction and drug metabolism; Site-directed structure modification of analgesics; Synthetic opioids; Antimalarials; Research decoding mechanisms underlying human virus genome transcriptional activation by the most potent xenobiotic; Dioxin
Yonghong Zhu, M.D., Ph.D. is currently the Senior Medical Director, Pharmacogenomics Liaison at Takeda Pharmaceuticals International. He is responsible for driving personalized medicine strategy in clinical development areas of immunology, respiratory diseases, and general medicine. Prior to joining Takeda in 2013, he worked as a Senior Clinical Scientist/Personalized Healthcare Leader at Genentech Product Development-Immunology & Infectious Diseases. In addition, his industry stint also included Roche Pharmaceuticals-Clinical Research & Exploratory Development-Virology, Sunesis Pharmaceuticals, Osel Inc. He did his postdoc work at DNAX Research Inc. (renamed as Schering-Plough Biopharma and now Merck Palo Alto). He holds a Ph.D. degree in Microbiology & Immunology from University of Rochester School of Medicine & Dentistry and also holds a medical degree from Nanjing University Medical School in China.
Biomarker-based patient clustering for drug development, personalized medicine and companion diagnostic development, viral hepatitis, immune modulation-based therapeutic strategy for chronic viral infection and autoimmune diseases
Dr. Mark Krystal is Director in the Department of Discovery Virology at Bristol-Myers Squibb, where he currently leads programs targeting direct acting agents against HIV-1 from early phase research through to initiation of clinical development. Mark has also been involved in the development or regulatory processes for the anti-HIV marketed agents Sustiva®, Reyataz®and Zerit®, along with the attachment inhibitor. In his 22 years at Bristol-Myers Squibb, Mark has led antiviral discovery programs against influenza virus, respiratory syncytial virus and HIV-1, where his team has identified numerous clinical candidates. Prior to joining Bristol-Myers Squibb, Mark was an Assistant Professor of Microbiology at the Mount Sinai School of Medicine in New York, where he pioneered studies that helped develop reverse genetic systems for negative strand viruses. Mark received his Ph.D. in Molecular Biology at SUNY Stony Brook and was a post-doctoral fellow in the laboratory of Dr. Peter Palese at Mt. Sinai. Mark has been an invited speaker at infectious diseases conferences, lectured in Virology courses at Yale and Mt. Sinai and has co-authored over 100 manuscripts and 16 patents. Mark currently serves on the editorial boards of Journal of Virology, Anitmicrobial Agents and Chemotherapy and Virology.
Drug discovery, integrase, capsid, HIV inhibitor, influenza and RSV.
Dr. Potts specializes in the control of adventitious agents (viruses, mycoplasma and prions) from a compliance, science and business focus. Her previous experience includes directing scientific and compliance activities for microbiology, raw materials, virology, mycoplasma, potency, environmental monitoring, cell bank testing for adventitious agents, TSE control in raw materials, nucleic acid method development and strategic planning for new technologies for the detection of mycoplasma and viruses. She has work experience with the USDA,ARS, the NIH (NIAID and NINCDS), the University of MN School of Veterinary Medicine and three biotechnology companies. Her Ph.D. research at the University of CA, San Francisco, School of Medicine was focused on the characterization of a new virus that caused congenital defects in the CNS of fetal lambs as a model for virus infections in humans.
Characterization of a new virus that caused congenital defects in the CNS of fetal lambs as a model for virus infections in humans.
Prasad Koka obtained his PhD in 1977 with a Biochemistry and Physical Chemistry as major and minor areas respectively from Texas Tech University, beginning with his graduate education in the year 1969 at University of Miami and completing my Master’s degree from University of Missouri Columbia, he have gradually over the years turned into a biomedical scientist, researcher and professor. Equipped with a dissertation in biophysics/biochemistry, he has performed hands-on research in photobiology, Bacteriophage, Retrovirology, Immunogenetics, transplantation, neuro-AIDS-dementia, and HIVusing humanized SCID mice. His research then turned into stem cells with emphasis on cancer stem cells generation in vitro and in vivo and the potential role of hematopoietic and mesenchymal stem cells in the relapse and susceptibility to therapies of cancer. For almost 25 years out of his 40 years of scientific work, the research focus to date has been on HIV/AIDS including cytopenias/hematopoietic in HIV infection, mother to child transmission of HIV infection through the placental membrane, and currently on the identification and characterization of host cellular factors that inhibit hematopoiesis in HIV infection (even in the absence of anti-retroviral drugs that also contribute to cytopenias). His Retrovirology and human virology expertise has been acquired or developed in Massachusetts Institute of Technology, Harvard Medical School, University of California Los Angeles, Torrey Pines Institute for Molecular Studies (San Diego), and presently at Haffkine Institute in Mumbai, India.
Molecular Factors; Mechanisms and Therapies of Hematological Disorders in HIV Infection and in Mother to Child Transmission of HIV Infection; Pre-clinical Translational Humanized In Vivo Model Systems - NOD/SCID-hu Mice (Human Fetal Thymus/Liver Conjoint Organ Growth +/- Autologous CD34 Cell Engrafted); Human Hematopoietic Stem Cell (hHSC) Differentiation in HIV Infection and in generation of Cancer Stem Cells using these Chimeric Humanized Mice In Vivo; Gene and Drug Therapy for Rescue from Hematopoietic Cell Dysfunction in HIV Infection; Safer and Greater Efficacy Drug for containment of HIV Replication; Host Cellular Factors in HIV Induced Hematological Disorders; Human Mesenchymal Stem Cells (hMSCs) in Vertical Transmission of HIV Infection; In Vitro Umbilical Cord Blood Derived hHSCs and Placenta Derived hMSCs in the Characterization and Susceptibility of Cancer Stem Cells to Therapeutic Strategies; Potential Homeostasis or Enlarged Pluripotency of Stem Cells Upstream or Downstream to hMSCs in Cancer Etiology; Cancer Cell Antigens-Biomarkers and Targeted Drug Delivery
Ivan Brukner entered into genomic era back in 1989 (ex-Yugoslavia), trying to describe and solve repeating sequence branching motif problem in building whole genome sequence. Next 5-10 years, his research was targeting sequence-dependent DNA structural problems, where contradictory puzzle about origin of DNA curvature and bending flexibility (crystallographic versus soft biochemistry data) was resolved (Italy, Germany and Canada). In 2000-2007, focus was directed toward design of nucleic-acid-based ideal point of care diagnostic device. Robust, multiplex, hybridization-based diagnostic device (which operates at standard room temperatures - in spite of ~90% sequence cross-similarity) was constructed and functionally tested. The universal protocol for selection of robust hybridization probes was result of this adventure. After joining Jewish General Hospital in Montreal (~2009), his work was becoming more clinically applicable, focusing on high volume molecular assays with strong financial and/or diagnostic impact they have on public health (MRSA, C. difficile, VRE). He realized the strong need for applicability of new molecular techniques in emergency, including whole genome amplifications, NGS, and definition of technological bottlenecks becomes his favourite troubleshooting activity. Fast and cost effective diagnosis/detection of different molecular events at DNA/RNA level is his passion.
Molecular Diagnostics; Virology; Microbiology; Genetics; Cancer and Recombination
Dr. Chil-Yong Kang, PhD, DSc, FRSC, is a molecular virologist and Professor of Virology in the Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry at WesternUniversity in Canada (1992-Present).
Born in South Korea, he did his undergraduate studies in both Korea and Denmark, immigrated to Canada in 1966 and became a Canadian citizen in 1971. He trained at University of Toronto and continued his postgraduate studies at McMaster University where he received a Ph.D. in virology under the supervision of Professor Ludvik Prevec in 1971. His postdoctoral training was in the U.S. underProfessor Howard Temin (1975 Nobel Laureate) at the University ofWisconsin-Madison(1971-1974).
He served as a Professor of Microbiology at the University of Texas, Southwestern Medical School in Dallas, Texas (1974-1982), Professor and Chairman of the Department of Microbiology and Immunology at University of Ottawa, Faculty of Medicine (1982-1992),and Dean of Science at the University of Western Ontario(Western University)(1992-1999).
In addition to his extensive teaching and administrative responsibilities, Dr. Kang has maintained an active research group. His research in molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome. Previously, hedeveloped a second generation vaccine against hepatitis B virus and an experimental vaccine against HIV/AIDS by using state-of-the-art technologies of genetic engineering and biotechnology. His SAV001-H vaccine began testing in human clinical trials in March 2012 and has successfully completed Phase I in late 2013.Dr. Kang has published 135peer reviewed research papersand 149scientific proceedings and abstracts in fields of virology, Immunology molecular biology, and medicine.He holds nine international biotechnology patents which cover over 70 countries in the world. Fourteen students received their Ph.D. degree and five students received their M.Sc. degree under Dr. Kang’s supervision. Dr. Kang has also trained well over 50 post-doctoral fellows and visiting professors from various institutions around the world.
Dr. Kang has received numerous prizes such as the Sahng-Huh Cultural Grand Prize in Academia (1991), Award of Excellence of the University of Ottawa (1991), Gold Medal for Ilchun Lecture (1998), Ho-Am Prize in Medicine (1999), the Order of Korea in Science and Technology (2002), the McMaster University Distinguished Alumni Award for 2007, the Paul Harris Fellow Award from Rotary International (2008), the Lifetime Achievement Award from the WesternUniversity(2009), Queen Elizabeth II Diamond Jubilee Medal (2012), selected as one of four Korean-Canadian Diasporas to Canadian Society by Canadian Government (2013) and the Scientist of the Year Award of the President of the Korean Federation of Science and Technology (2013).Dr. Kang was elected as a Life-time Fellow of the Royal Society of Canada Academy of Science (1993)and an elected Life-time Member of the Korean Academy of Science and Technology(1997).
He continues to serve as a grant selection committee member for various federal granting agencies in Canada and the USA, including CIHR, NHRDP, NSERC, and NIH. He is a member of the Board of Directors of numerous research institutions and foundations. Dr. Kang serves as a reviewer for the Journal of Virology, Journal of Infectious Diseases, Virus Research, Virology,Journal of Biological Chemistry and Canadian Medical Association Journal.
Molecular virology includes the development of viral-specific antiviral therapeutic agents and efficacious vaccines against various human viral diseases including AIDS, hepatitis and hemorrhagic fever with renal syndrome.
Roger Pomerantz is Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. He oversees all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances, and chairs the Merck Venture Research Fund. He is also chairman of the Early Development Research Committee at Merck.
He joined Merck's Research Laboratories as Global Head of the Infectious Diseases Franchise and Senior Vice President, in charge of all anti-viral, anti-bacterial, anti-fungal and anti-parasitic agents, including global strategy. He also led the integration of the infectious diseases franchises of Merck and Schering Plough into a single global franchise.
Prior to joining Merck, He was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents world-wide (including virology, tuberculosis, anti-bacterial agents, and diagnostics). He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc.
He received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate, Dr. David Baltimore. Later he was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School.
He has published over 300 articles in the scientific literature and presented over 200 invited lectures, nationally and internationally, concentrating on the clinical research, molecular pathogenesis and especially latency of human immunodeficiency virus and other pathogenic human viruses.
He is Board Certified in both Internal Medicine and Infectious Diseases.
HIV latency and eradication, HIV molecular pathogenesis, and neurovirology of HIV.
Kevin Whitby PhD graduated from the University of Bristol before gaining a Masters degree in virology from the London School of Tropical Medicine and Hygeine. He gained his PhD working in the clinical virology labs at UCH in London. During the 1990’s he developed one of the first practical, quantitative assays for HCV and co-authored a number of papers describing early developments in interferon therapy of HCV infection, including the first paper to describe interferon ribavirin combination therapy.
Working as a post-doc for a small UK based biotech company (Virogen Ltd) he studied the use of alpha glucosidase inhibitors in flavivirus infections leading to a second post doctoral position at Washington University in St Louis publishing both on the potential role of alpha glucosidase inhibitors in dengue virus infection and the role of complement in the interferon response pathway during West Nile virus infection.
He has a long history in antiviral drug discovery and until recently led HIV exploratory projects at Pfizer where he described several inhibitors with novel mechanisms including both catalytic and non-catalytic site integrase inhibitors as well as a small molecule HIV restriction factor.
He joined the medical department at Gilead Sciences as a medical scientist in December 2013 where he supports the company's efforts to transform care for patients with viral hepatitis.
Antiviral therapy in chronic viral infections (HBV, HCV and HIV) from discovery, mechanistic evaluation through clinical studies to their use in transforming therapy for patients.
King Saud bin Abdulaziz University for Health Sciences
United Arab Emirates
Ra'ed Abuodeh is an Associate Professor of Molecular Biology and Microbiology at King Saud Bin AbdelazizUniversity for Health Sciences (KSAU-HS) in Jeddah-KSA. He received his Ph.D. from Idaho State University, working on systemic fungi using Blastomycesdermatitidis as a model. This was followed by a post-doctoral fellowship at the University of Texas Southwestern Medical Center-Dallas, where he worked on IgM molecular switching between the membrane form and the secretory form. Subsequently, he earned his spot as a lead researcher at the Valley Fever Center of Excellence- University of Arizona Medical College, Tucson, where he worked on systemic fungal molecular biology, and this time on Coccidioidesimmitis. After that he decided it was time for a change of scenery (and weather) and moved to sunny Sharjah, UAE, where he was offered faculty post at the University of Sharjah, Medical Lab Sciences Department. In addition to teaching, he involved in research in the fields of molecular microbiology, diabetes, and cancer. He recently collaborated with colleague at Qatar University, Dr. G. Nasarllah, to conduct research on viral molecular epidemiology (TTV, HGV, HEV, and EBV). He was also the adviser for several undergraduate and graduate students on different research projects. He currently resides in Jeddah, with his wife and children
Molecular Microbiology; Molecular Epidemiology; Vaccine Development; Metabolic Syndrome/Diabetes Research
Farshad Guirakhoo is currently the Chief Technical Officer of Vaxess Technologies, Inc.(www.vaxess.com), an innovative life sciences company developing a novel vaccine stabilization technology. Prior to this, he served as the CSO at Hookipa Biotech, a privately owned company developing vaccine against cytomegalovirus virus and cancers using a novel technology based a non-replicating viral vector. Prior to joining Hookipa, he was Senior Director of External Research and Development at Sanofi Pasteur, the Vaccine Division of the Sanofi Group. Prior to joining Sanofi Pasteur in 2007, he was with Acambis for 15 years, where he headed research and co-invented the Chimeri Vax (R)-Technology platform in association with St. Louis University. This platform has successfully been applied in the development of vaccines that are either registered/marketed (e.g. IMOJEV™, a single dose Japanese Encephalitis vaccine and PreVenile™ veterinary West Nile (WN) vaccine) or are in late stages of clinical development (Tetravalent dengue vaccine, completed Phase 3 trials, and WN human vaccine completed Phase 2 trials in elderly population).
He has broad experience in the application of genetics, gene expression technologies and molecular virology for the construction and production of recombinant proteins, human antibodies and attenuated viral vaccines for prevention and treatment of infectious diseases. He is the author of over 80 peer-reviewed publications, including book chapters, and holds multiple patents.
He received his PhD in Virology from the University of Vienna, Austria, holds a M.Sc. in Cell and Molecular Biology, and a B.Sc. in Biology. He has been awarded the National Research Council Post-Doctorate Award and studied at the National Centers for Disease Control (CDC), Division of Vector-Borne Infectious Diseases (DVBID), in Fort Collins, CO
Dr Eddie Blair is CEO of Gene First Ltd, a company using proprietary molecular technologies to better diagnose cancer and infectious disease. He remains Managing Director of Integrated Medicines Ltd (IML), a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, founding director of Integrated Magnetic Systems Ltd (IMSL), and a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised medicines and offers occasional bespoke courses based on his best-selling books.
Use of diagnostic testing to improve anti-viral drug efficacy (influenza, HIV, HCV).
Fabrizio Maggi is MD graduated at the University of Pisa, Specialist in Microbiology and Virology, Ph.D. in “Clinical and Fundamental Virology” at the University of Pisa. He is Clinical Assistant at the Clinical Virology Unit and Regional Reference Center for Innovative Diagnostics of Pisa General Hospital (Azienda Ospedaliera Universitaria Pisana)since 2001. He is teaching as Adjunct Professor at the specialization school in “Microbiology and Virology”, University of Pisa. He had awards for research on HIV from ANLAIDS Association (National Association against AIDS), Unesco, and International Foundation for AIDS Research and for research on HIV from the Istituto Superiore di Sanità. He helds teaching courses of Microbiology and Clinical Microbiology at the Faculty of Medicine and School of Laboratory Technician of Pisa University, and lessons at post-graduate courses in scientific areas. He is member of various scientific societies such as Italian Society of Microbiology, Italian Society of Virology, Italian Society of Medical Virology, and Association of Italian Microbiology Clinicians, and serves as referee for a number of international scientific journals. He has published over 250 refereed papers and abstracts as well as several chapters in national and international scientific books.
Natural history and pathogenesis of anelloviruses infection and development of methods for anelloviruses diagnosis. Additional areas of research include emerging respiratory viruses (particularly single-stranded circular DNA viruses, metapneumovirus, bocavirus), hepatitis C virus, human immunodeficiency virus, feline immunodeficiency virus, and diagnostic virology.
Prof Waheed Uz ZamanTariqis a graduate of King Edward Medical College, Lahore, a Fellow of College of Physicians and Surgeons, Pakistan, The Royal College of Pathologists, London and The Royal College of Physicians, Edinburgh. He was trained in Infectious Diseases and Virology in St Thomas’ Hospital London, Regional Virus Laboratory, Manchester, Monsall Hospital and Manchester Royal Infirmary, England. He is also MA and MOL in literature and a PhD in classical medical literature of the Indian Subcontinent, in the subject of Persian literature.
An Academician, soldier and a field worker. He is currently working as a Consultant Microbiologist and Virologist at Tawam Hospital, Al Ain, UAE. He is a retired Brigadier of Pakistan Army. He had been head of Department of Virology at the Armed Forces Institute of Pathology, Rawalpindi, Pakistan and of Professor of Virology at the University of Health Sciences, Lahore and Armed Forces Postgraduate Medical Centre, Rawalpindi. He had been on the visiting Faculty of Liverpool School of Tropical Medicine, England. Formerly, he was Editor Pakistan Journal of Pathology. He had authored 135 articles and half a dozen of books. He was the member of Regional and Global task force of the United Nations on HIV/ AIDS in troops. He is member of WHO’s Committee on Polio Eradication Certification. He is WHO’s member of team of Poliovirus eradication. He has been involved in the Lassa Fever and HIV control in Liberia, Sierra Leone and Somalia on behalf of the United Nations.
Control of CCHF, Dengue virus, Influenza and Hepatitis E Virus.
Dr. Friew is an Ethiopian born scientist who comes to USA to study chemistry and biological science in 1993. Before that he studied general Agriculture and worked as a Development Agent in the Ministry of Agriculture, Ethiopia. His experience with the enduring poverty and lack of health care in the rural Ethiopia motivated him to become a scientist. After coming to US he pursued his lifelong dream to study science and technology and had accomplished a great deal since then.
He is highly skilled researcher and consultant with a Ph.D. who has experience in a variety of areas of Biomedical Research and international consultancy. In his position with The Laboratory of Viral Diagnostics (LVD) at the Institute of Human Virology (IHV), he was an integral member of the clinical trials program (FDA trials for rapid HIV tests), performed serologic and molecular methods, evaluated rapid test kits for the international project with PSCM, and headed the SMARTube projects (FDA 510K submission). He also spent time in Africa evaluating a reference laboratory for their quality control and assurance capabilities and made recommendations for improvement. Upon completing his assignment, his work have saved more than a Million dollar in just a monetary value.
During his Postdoctoral study in Dr. Vinay K. Pathak's Laboratory at The National Cancer Institute Frederick (NCI-Frederick)/NIH in the HIV Drug Resistance Program Viral Mutation Section, successfully developed a system to study interactions between human enzymes APOBEC3G (block HIV-1 replication in non-permissive cells) and other molecules. He successfully studied in vivo and in vitro interactions between A3G, HIV-1 Gag, and RNA using bimolecular fluorescence complementation technology and other biochemical analyses. He has presented these studies orally and in poster presentations at international meetings. In addition, these studies were published in the peer reviewed journals.
He has a set of skills developed with years experience working in the most technologically advanced places using modern cutting age technologies. He is proficiency in virology, immunology, molecular and cell biology and cellular imaging skill and knowledge will be valuable assets to make a difference in the care of his clients. His immense experience will be valuable to tackle and solve every day clinical and basic research laboratory problems.
Besides his passion for science and technology the main inspirational force to pursue his dream was to make difference in human health condition. He founded IntBiotechnologies, LLC an International Biomedical Products Supplier and Consultant company to advance his life goal to be a force for the betterment of human health.
Infectious diseases diagnostic including identifying molecular target for the development of viral diagnostic: to provide expertise and support from a variety of experts in the biomedical field in order to establish, strengthen, and further develop clinical, public health and research laboratories throughout the world.
Saeed Bayanolhagh is the head of HIV/AIDS research laboratory in Iranian HIV research center. He founded a HIV/AIDS basic science laboratory that performs testing for a full range of HIV/AIDS diagnosis tests and research projects in Iranian HIV research center in Imam Hospital in heart of Tehran, Iran. This lab known as the central lab for any related to HIV basic subjects and have good facilities such as cell cultures lab and cell based equipment’s, PCR and Real Time PCR machines and gene and vector manipulation services, Protein assays such as ELISA, Chemi-luminescence, EliSpot, Western blot and Flow Cytometry instrument, Protein Purification and etc. He has worked for at least 10 years in these techniques and teaches these methods on behalf of his students. It’s our honor to say this day more than 10 projects were and many researchers are working there. He has always enjoyed HIV basic science and specifically HIV vaccine research and his thesis was “Multiple HIV-1 antigens vaccine based replication-defective recombinant adenovirus vector and evaluation of immunologic properties.”
HIV, HIV diagnosis methods, Immunopathogenesis of HIV, Immuno-viral interaction and HIV vaccine.
Dr. Noah is the Manager of Virology in the Drug Discovery Division and is also an adjunct faculty member at The University of Alabama at Birmingham. He received his Ph.D. in Biochemistry in 1999 from North Carolina State University, where he studied the structure of the bacterial ribosome, function of catalytic RNA, and the effect of antibiotics on both. After postdoctoral studies during which he studied transposable intron RNAs for use as gene therapy vectors and diagnostics at The University of Texas at Austin, Dr. Noah joined the staff at Southern Research. He has both drug discovery and basic research programs in infectious disease research that focus on developing new antimicrobial drugs. His discovery programs encompass target identification and validation, high-throughput screening assay development, and mechanistic characterization of potential therapeutics. His NIH-funded research program investigates how multiple RNA viruses (Influenza, RSV, Dengue, Venezuelan Equine Encephalitis, and SARS) interact with host kinases to promote their own replication and spread. Lastly, he is a Subject Matter Expert for biological WMD for a Defense Threat Reduction Agency-sponsored Biological Threat Reduction Integrating Contract for former Soviet Union countries. He has industrial experience in assay development in GLP and GMP facilities, research experience in enzyme kinetics, structure determination, and RNA-protein interactions, including investigating these interactions using photochemistry, mass spectrometry, and atomic force microscopy. In addition, he has government and commercial experience in antiviral discovery and evaluation through high-throughput screening. This work has led to multiple publications in peer-reviewed journals, book chapters/reviews, and patent applications. He has served on peer review panels (Biodefense and Microbial Vaccine Development) for the National Institutes of Health and is a member of the editorial board for the journal Antiviral Research. He is also an ad-hoc reviewer for the Journal of Biomolecular Screening, PLOS One, the Journal of Infectious Disease, American Journal of Respiratory Cell and Molecular Biology, and the Journal of Ethnopharmacology.
Luis M. Branco, Ph.D., Co-Founder, Zalgen Labs . He has extensive expertise in multiple facets of research and development of chimeric, humanized, human, and affinity maturation of recombinant antibodies for human use. During 15 years in industry he was directly involved in the development of licensed antibody therapeutics, such as MedImmune’s Synagis (Palivizumab), Human Genome Sciences’ Benlysta (Belimumab) and ABthrax (raxibacumab), as well as additional antibodies under clinical evaluation (MEDI’s Numax [motavizumab], HGS’ CCR5mAb004, HGS-ETR1 [Mapatumumab]. His research interests also focused on development of industry leading technologies for acceleration of stable cell line development with high regulatory compliance, aimed at reducing timelines and costs in the development path toward IND filings. He was a co-founder of BioFactura, a biotech company in the Washington-D.C. area dedicated to development of therapeutics for Biodefense, where we served as V.P. Research, and Chief Science Officer from 2005 - 2008. Since 2008 he has been actively directing R&D aspects of the Viral Hemorrhagic Fever Consortium’s Lassa fever program, and performing field research work in Sierra Leone and Nigeria. These efforts have resulted in the CE marking and commercialization of first-in-class rapid diagnostic test for Lassa fever (reLASV RDT™). He is currently actively involved in the development of first-in-class immunotherapeutics for prophylaxis and post-exposure treatment of Lassa fever and other arenaviral infections. He is the inventor of a novel mammalian cell-based biomanufacturing system that is employed in the production of Zalgen’s products.
Diagnostics, vaccines, therapeutics for arena viral infections, Mammalian expression systems, Novel human stem cell technologies.
Obina Nnedu is the associate program director for the infectious diseases training at Ochsner Clinic Foundation. His duties primarily include teaching and mentoring physicians undergoing infectious disease training. He also provides infectious disease consultation on patients. He has extensive experience conducting research studies and projects in developing countries. He has been involved in research projects in Zambia, Jamaica, Sierra Leone and Kenya. He spent a year in Kenya providing care to HIV patients where he also served as a mentor to local clinicians. While working in Kenya, he was also the principal investigator in a research project that focused on the interactions between HIV and malaria in co-infected patients. He is passionate about medical education and international health. He received his bachelor’s degree from Auburn University and went on to complete his medical degree and master’s degree in public health from the University of Alabama. He completed his internal medicine residency at Tulane University School of Medicine. He went on to complete a fellowship in Infectious Diseases at the University of Washington. He is board certified in Internal Medicine and Infectious Disease.
Medical education, International health, HIV and tropical infectious diseases.
Abdel-Moneim is a Professor in the Department of Microbiology (Virology Division) at Taif University of Taif’s College of Medicine, Saudi Arabia and also in the Department of Virology, Faculty of Veterinary Medicine, Beni-Suef University, Egypt. He has 30 publications, 19 in peer-reviewed international journals and 6 contributions in proceedings and scientific books as well as 162 submissions to the GenBank. He is one of the editorial board of World Journal of Virology, Virology Discovery, Microbes and Health, WebMed Central, and Saudi Journal of Health Sciences as well as an ad hoc reviewer for a number of international scientific peer review journals including vaccines, J Med Virol, Viral Immunology, Journal of Virological Methods and many others. He is a member of different societies of Virology including, American Society of Virology, American Society of Microbiology, and Egyptian as well as Arab society for Virology, He supervised many predoctoral and postdoctoral scientists from Egypt. He worked as University Professor and consultant for both Governmental and private sectors for many years in Egypt.
Molecular characterization, evolution and genotyping of important viral infection in humans and animals. Understanding of pathogens-host interaction is another research priority.
Jose Miguel Azevedo Pereira is Assistant Professor of Virology in the Department of Microbiology and Immunology at Faculty of Pharmacy, University of Lisbon. He received is Pharm D in 1987 and his PhD in 2001 from the Faculty of Pharmacy, University of Lisbon. During his graduate and postdoctoral studies he mainly focused on the HIV tropism, namely the mechanisms of viral interaction with cellular receptors using HIV-2 as a model. Since 2002 he is Principal Investigator and Head of HIV tropism and Pathogenesis Unit at Retrovirus and Associated Infections Unit - Molecular Pathogenesis Center (URIA-CPM). He has received research fundings from Portuguese Foundation for Science and Technology (FCT), from Merck Sharp & Dhome, from Gilead Sciences and from bioMerieux for work in three main research areas: “HIV-2 Interaction with Cellular Receptors” (FCT Research Grans), “HIV Viral/Sera Library” (grants from MSD and Gilead Sciences) and “Evaluation of Rapid Tests for Early Detection of Anti-HIV1/HIV-2 Antibodies” (R&D project financed by bioMerieux Portugal). Since 2014 he started a new research project funded by FCT and Portuguese Ministry of Health entitled “HIV-2 interaction with macrophages and dendritic cells: implications in the reduced pathogenicity of HIV-2”. During the last decade, he have been committed to understand why HIV-2 is significantly less pathogenic than HIV-1. Based on his previous work he suggested that one of the factors that greatly contribute to the lower virulence of HIV-2 is related with the efficiency with which HIV-2 interacts with cellular receptors. Currently he aims to further gain insight into the reasons of this different pathogenic potential, exploring the interaction of primary HIV-2 with dendritic cells and macrophages. He has received several scientific awards from both public and private institutions: “Award Dr. Jose Luis Champalimaud 2002 - HIV Basic Research” (Portuguese Ministry of Health); “Award Camara Pestana 2003 – Scientific research in Microbiology” (Camara Pestana Institute); “Award Maria Amelia de Mello for Health Sciences 2004 - Basic Research” (Jose de Mello Saude Group) ; and “Award Dr. Ricardo Jorge de Saude Publica 2005” (Portuguese National Institute of Health). Since 2005, he is Head of the Virology and the Clinical Virology courses at Faculty of Pharmacy, University of Lisbon and he mentored over 20 students (PhD and Master students). He is member of various scientific societies and served on international and national grant review panels as well as referee for a number of international scientific journals.
He has published over 150 papers in peer reviewed journals, book chapters and abstracts, focusing on HIV interaction with cellular receptors and viral pathogenesis.
HIV interactions with cellular receptors; pathogenesis of HIV infection; HIV-TB co-infection;
Pamela J Skinner is faculty member of the Department of Veterinary and Biomedical Sciences at the University of Minnesota. She has a broad background in molecular biology and immunology and she interested in understanding disease pathogenesis. As a graduate student in the lab of Dr. Harry Orr, she worked to gain understanding to mechanisms underlying spino-cerebellar ataxia pathogenesis. During her postdoctoral studies in the lab of Dr. Ashley Haase, she developed an in situ tetramer staining (IST) technique to visualize antigen-specific CTL in tissues, a technology they continue to use today in her lab to study virus-specific CTL in tissues. Since 2002, she has been continuously funded, have successfully administered research projects (including staffing; research training; animal and human biosafety compliance and budget management), collaborated with other researchers, mentored over 30 students and produced peer-reviewed publications. Her current efforts are devoted to understanding lentivirus and prion disease immunopathogenesis and the development of novel treatments for these diseases.
HIV and SIV immunopathogenesis, novel immunotherapies to treat or cure HIV, HIV/SIV vaccine development and prion diseases
David Robert Warren, MD received his M.D. degree from Case Western Reserve University (1985-1990) with a minor in Medical Ethics.During his post-graduate residency in Primary Care Internal Medicine at Montefiore Medical Center of Albert Einstein College of Medicine (1990-1993) and during his tenure at Cornell Medical College (1993-1999), he volunteered for the Bronx/Harlem Needle Exchange, the first illegal needle and syringe exchange program in New York City, which was subsequently legalized by New York State in July 1992. As a result, incidence of new HIV infections among IDUs in NYC dropped from 4% per year (1990–1992) to 1% per year (1999–2002) and HIV prevalence decreased from 50 % to 15 %. The number of syringes and needles exchanged per year in NYC increased from 250,000 to 3 million.
He began focusing his career on novel treatments of HIV infection when he joined the Center for Special Studies (New York Presbyterian, 1993-1999)one of the first multi-disciplinary in- and out-patient HIVprograms in NYC.As faculty of the department of medicine of Weill College of Medicine of Cornell University (1993-1999),he collaborated with Dr. Kendall Smith studying the effects of IL-2 on HIV-infected adults. One important outcome was characterizing the IL-2 receptor affinity for T-cells (high affinity) and NK cells (low affinity). This translated to clinical use of ultra-low dosing of IL-2, which increased the CD4 cell count without side effects associated with higher treatment-limiting doses of IL-2 that had been in use.
David joined the faculty of SUNY Downstate Medical Center (1999-2003) and became Medical Director of the Ryan-White grant-funded multi-disciplinary STAR Program and Outpatient Clinic of the HIV Center for Women and Children where the majority of patients were women of color. In addition to directing clinical care, his responsibilities included leading clinical education for Brooklyn, Queens and Staten Island and for clinical research.
During the past 10 years, David has worked for two biotech/pharmacompanies- Gilead Sciences (2003-2012) and Abbvie (2012-2014). He worked on the clinical development of the Gilead’s single tablet regimen, Stribild® and the pharmacoenhancer, cobicistat from first-in-human studies through NDA filing. He also volunteered one clinic session per week at Haight Ashbury Clinic (2005-2012). While at Abbvie (2012-2014), he was apart of Global Medical Affairs, Virology (HCV, HIV and RSV) for Japan, Asia-Pacific, Australia, and China.He has been a reviewer for AIDS.
Johan Lennerstrand Associate Professor, Section of Clinical Virology, Department of Medical Sciences Uppsala University, Sweden. He received a PhD in Medical Virology in 1996 at Uppsala University. He did his postdoctoral work in 1998 – 2000 with Dr Brendan Larder at Virco UK, Cambridge. In 2005 he became Associate Professor in Experimental Virology at Karolinska Institutet, Stockholm.He started his professional career more than 20 years ago in the industry at Sangtec Medical, Stockholm, where he developed tumour marker and HIV RT assays. During the postdoctoral period his research was directed towards HIV drug resistance and this research was continued in 2001 at Department of Clinical Virology, Karolinska Institutet. In 2005 - 2007, Johan Lennerstrand was a visiting scientist in Professor Raymond Schinazi´s laboratory at EmoryUniversity, Atlanta. Currently, he is working at Section of Virology, Department of Medical Sciences, Uppsala University. His present research interests involve assays for studying virus and cancer drug resistance. His list of publications includes papers, reviews and patents related to resistance assays of Hepatitis C,HIV, Influenza virus andtumour markers.He has been an invited speaker to international meetings and at pharmaceutical companies. He is the founder of the meeting; Nordic Conference of HIV and Hepatitis Drug Resistance and Treatment Strategies.
Hugo Arias Pulido is a Research Associate in the Department of Radiology in Geisel School of Medicine at Dartmouth College in Lebanon, NH, USA. He received a PhD in Biology in 1990 at the Russian Academy of Science Institute of Biophysics in Pushino, Russia. He did his postdoctoral work in molecular biology at the Karolinska Institute, Stockholm from 1990 to 1992, and in translational cancer research in cervical cancer with Dr.VVV Murty at Columbia University, New York in 2000. During this postdoctoral period his research was directed towards identifying prognostic biomarkers of patient outcome as well as to identify the role played by the human papillomavirus in cervical cancer. This later activity was performed in the Laboratory of Prof. Cossette Wheeler in the Department of Molecular Genetics and Microbiology, the University of New Mexico School of Medicine. His present research interests involve the possible association of viruses with breast cancer, and the development of Patient-Derived Xenografts models in breast cancer. The ultimate goal of these studies is the validation of small inhibitor molecules, oxygen- and antibody-based therapies as well as to identify novel gene signatures that will predict response or resistance to neoadjuvant chemotherapies. These signatures may generate lead biomolecules that will be characterized as predictive and prognostic biomarkers and potential novel therapeutic targets. He is also a reviewer for the Gynecology Oncology, (Top Reviewer 2010-2011), Breast Cancer Research and Treatment, Cancer Research, British Journal of Cancer, International Journal of Cancer, International Journal of Gynecological Cancer, BMC Cancer, BMC Molecular Cancer, and Bioinformatics.
Viruses and cancer; Molecular mechanisms of tumor progression; Biomarkers of tumor progression; Prognostic and predictive biomarkers; Role of environmental and host genetic factors as surrogate biomarkers of response to current therapeutic treatments; Natural history of inflammatory breast cancer and triple negative breast cancer in young women
Luis Men ndez-Arias
Spanish National Research Council (CSIC) - CBMSO
Luis Menendez Arias (born in 1961, Oviedo, Spain) is a Research Professor of the Consejo Superior de Investigaciones Cientificas (CSIC, Spanish National Research Council) and Group Leader at the Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, where he has been working since 1994. His research is mainly devoted to understanding structure-activity relationships in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), elucidating mechanisms of HIV-1 resistance to antiretroviral drugs, and understanding HIV replication fitness.
He was graduated from the Complutense University of Madrid, Spain in Biology in 1984, and obtained his Ph.D. in 1989 at the Department of Biochemistry and Molecular Biology of the Faculties of Biology and Chemistry of the same university. Between 1990 and 1994, he was trained as a postdoctoral fellow in the Frederick Cancer Research and Development Center, Frederick, Maryland, USA, where he conducted studies on the biochemical properties of retroviral proteases and their implications in virus maturation and antiviral therapy.
He is author of >100 peer-reviewed research papers. He is Academic Editor of the journal PLoS ONE, and member of the Editorial Boards of Antiviral Research, Antiviral Therapy, Virus Research, Viruses and World Journal of Virology. He also served as guest editor for special issues of the journals Virus Research (‘Retroviral reverse transcription’, co-edited with Dr. B. Berkhout and published in 2008), Viruses (‘Retroviral enzymes’, published in 2010) and Current Opinion in Virology (‘Antivirals and drug resistance’, co-edited with Dr. D. D. Richman and published in 2014). In March 2013, He was an invited fellow of the Japan Society for the Promotion of Science.
Understanding structure-activity relationships in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT); Elucidating mechanisms of HIV-1 resistance to antiretroviral drugs; Understanding HIV replication fitness
Professor Mahmoud YM Taha (BVMS, MSc, PhD, Ml.Biol, DcPath is a graduate of Baghdad Vet. Medical college 1979. Then he obtained MSc degree in Virology. After that he trained on Diagnostic virology in Rasheed Military Hospital. In 1984 he became a member of the scientific staff of Dental College, Mosul University. In 1990 he obtained his PhD degree in virology from Glasgow University and appointed as Dean Assistant for scientific research in Dental College, then appointed as Head Department of Dental Basic Science and Director of Diagnostic lab in the Dental hospital, Mosul University. He has published more that 50 papers and supervised MSc and PhD students in the field of virology and oral microbiology. Prof. Taha is a member of Editorial Board of many journals in virology and Dental sciences. Prof. Taha has published many books in the field of Oral Microbiology and Virology.
Human herpes viruses specially HSV-1, EBV, CMV and their relations to periodontitis, periapical lesions and aphthous stomatitis as well as the role of interleukins in Different t oral Diseases
Mohamed Haroun, a graduate of University of Khartoum, Sudan, is Associate Professor of Veterinary Virology and Immunology and Staff Member of the Faculty of Veterinary Science, University of Nyala, Sudan. Beside, He is currently entitled “Virology Expert” at Veterinary Laboratory, Department of Animal Resources, Ministry of Environment, State of Qatar, a diagnostic and a future research unit aiming at achieving the international standard levels for testing of viral diseases as per ISO Norms.
The successive association of Dr. Haroun with paramyxoviruses during his MVSc and PhD graduate programs has given him a broad base and a respectable insight playing with the disease related viruses. His investigation on “analysis of cellular and humoral immunity to rinderpest viruses (RPV)” in both temperate and zebu cattle during the PhD study program has furnished him with a solid experience in viroloical, immunological and molecular techniques that paved him the way to bridge the professional boundaries, building handy research ties with some renounced research oriented institutions such as Pirbright Institute.
The 24 years of continuous association with teaching, research, administration and consultancy in universities and affiliated institutions has established strong interdisciplinary research funding and conducting institutions such as Qatar Foundation and Cornell University. This situation has experienced current research projects on foodsafety and foodborne pathogens and projected attention to viral zoonosis. In addition to his concern with molecular characterization and phylogenetic analysis of Newcastle disease viruses in Qatari avid species, He is currently supervising graduate projects on PPRV and EHV.
Richard F Pfeltz, PhD, is a research microbial physiologist and holds the position of Staff Scientist in the Microbiology R&D Department of the Diagnostics segment of Becton Dickinson (BD). BD is a Fortune 500 manufacturer of FDA- and USDA-regulated in-vitro infectious disease diagnostics, medical devices, and microbiology supplies that employs the Six Sigma business management strategy. He joined BD in 1999 after receiving a doctorate from Illinois State University for work with vancomycin intermediate-susceptible MRSA (VISA). He is currently BD-Baltimore’s Biosafety Officer and Manager of its R&D BSL-3 (TB) lab. Areas of expertise include product development, detection and culture of bacteria, fungi and mycobacteria (notably blood culture and TB culture), growth media formulation and chemical analysis, specimen processing, antimicrobial susceptibility testing, rapid diagnostic methods, protein expression, fermentation, clinical MALDI-TOF, laboratory automation, and novel technology evaluation. He has also made four trips to Africa for BD’s PEPFAR initiative to build TB diagnostic capabilities. Recent accomplishments include leading the development of a series of new lyophilized antimicrobial products, biosafety for a molecular diagnostics platform, and development of a protocol for diagnostic instrumentation service personnel to enter clinical labs that handle Ebola-containing specimens.
Detection and culture of bacteria; Fungi and Mycobacteria (notably blood culture and TB culture); Growth media formulation and chemical analysis; Specimen processing, antimicrobial susceptibility testing; Rapid diagnostic methods; Protein expression; Fermentation; Clinical MALDI-TOF; Laboratory automation and Novel technology evaluation
Arun Kumar Adhikary received Ph.D from Faculty of Medicine, The University of Tokyo. He was awarded the Long Term JSPS post doctoral fellowship and performed his work (2002-04) on Virology at the National Institute of Infectious Diseases, Tokyo, Japan. In 2013 Dr. Adhikary joined as Associate Professor in the Unit of Medical Microbiology, Asian Institute of Medicine Science and Technology (AIMST) University, Malaysia. He completed JSPS Long Term Invited Research Fellowship program (2013-14) on virology at the National Institute of Infectious Diseases, Tokyo. His passion is Human adenovirus and over the last 17 years he conducted studies on molecular epidemiology of human adenoviruses and succeeded to develop different molecular identification methods for clinically important HAdVs.
Genome sequencing, analysis and phylogenetic analysis of respiratory, enteric and oculopathogenic viruses. Development of molecular diagnostics. Genomic fingerprinting of viruses with special emphasis on clinically important human adenoviruses.
Peter Delputte is Professor of Microbiology and Cell Biology at the Laboratory for Microbiology, Parasitology and Hygiene (LMPH) at the University of Antwerp. He is a bio-engineer with a biotechnological background. He has a PhD in Virology with a focus on virus entry and macrophage cell biology. He received an EMBO postdoctoral fellowship for a research stay at the Laboratory of Prof. Paul Crocker (University of Dundee) to study the role of sialoadhesin in macrophages and he was a visiting postdoc at the Laboratory of Prof. Anne Dell (Imperial College London) to study the role of virus glycosylation for virus entry in macrophages.Besides his interest in basic research, he has extensive experience with research valorisation projects (vaccine development, creation of cell lines for industrial vaccine production and development of a technology to target macrophages) and he succesfully completed a programme in Technology Transfer Management from the Vlerick Leuven Ghent Management School.
Mechanism of entry of Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus Immune evasion, Development of recombinant antibody – fusion proteins to target macrophages via the macrophage-specific receptor sialoadhesin (Siglec-1 ; CD169), Role of the macrophage-specific receptor Sialoadhesin (CD169; Siglec-1) in interaction of macrophages with pathogens, Development of pathogen-specific monoclonal antibodies for use in research, diagnosis and therapy
Cavan Reilly completed his MS in Statistics followed by a PhD in Statistics in 2000, both from Columbia University. He was an Assistant Professor in the division of Biostatistics in the School of Public Health at the University of Minnesota from 2000-2007. At present, he is the Associate Professor in the division of Biostatistics in the School of Public Health at the University of Minnesota.
Statistical analysis of high dimensional data obtained using RNA-Seq, LC-MS technologies and Bayesian inference, HIV/AIDS research
The long-term objective of his research program is to study virus-host interactionswith the aim understanding the biological complexity of virus-host interactions and translating it into new antiviral strategies and agents for the effective control of viral infections. His group is using cutting-edge molecular biology, microscopy, classical and molecular virology approaches to decipher the interplay of the key molecular factors of the virus infection that contribute to the unique pathogenesis of the animal viruses that are important for human and animal health
James Tianjian Li is an experienced scientific leader with over 15 years of experience in academia and industry. He earned his Bachelor of Science degree in Computer Science from Rutgers University in 1992. He received his Ph.D. in Molecular Biology from University of California, Los Angeles in 1998 and did his post-doctoral work in neuroscience at University of California, San Francisco. Shortly after, he joined biotech industry and worked on genome editing using engineered zinc-finger-nucleases (ZFNs) and later on chimeric antigen receptor modified T cells (CAR-T) for immunotherapy of cancer. He has extensive experience with retrovirus, lentivirus, adenovirus, and adeno-associated virus. He has published in Nature, Immunity, and other prominent peer-reviewed scientific journals and have filed several patent applications. Dr. Li’s scientific interest includes genome editing, gene and cell based therapy, and immunotherapy of cancer.
Retrovirus; Lentivirus; Adenovirus; Aav; Tittering By Flow And Pcr Assays
Chen is Research Professor in the Department of Surgery, City of Hope National Medical Center, and Department of Virology, Beckman Research Institute of the City of Hope. In addition, he holds an associate professor position in the Department of Radiation Medicine and Applied Sciences, Rebecca & John Moores Comprehensive Cancer Center, University of California, San Diego. He has been working in the field of poxviruses for more than 25 years, with the interest in both translational and basic aspects of these viruses. He conducted extensive studies on the genomics and pathogenesis of poxviruses, and has been interested in developing poxviruses as a vector for HIV and cancer vaccines, and as an agent for oncolytic virotherapy of cancer. Prior to joining City of Hope, he was Vice President of Research and Development overseeing the development of the new generation poxviruses for tumor diagnosis and therapy at Genelux Corporation. Among numerous oncolytic virus candidates he and his team developed, two of them are currently being evaluated in phase I clinical trials. One of these clinical trial viruses was handpicked by him.
He won many awards and honors, including the first prize of the Science and Technology Progress Award from the China’s Ministry of Health, the NERD (the Novel Experimental Research Developments) Achievement Award from the National Institutes of Health (NIH), and Genelux’s Distinguished Achievement Award. He was invited as Lead Gust Editor to edit the special issue on oncolytic virus for the journal “Advances in Virology”. Part of his work on the effect of IL-4 on the pathogenesis of ectromelia virus was reported in the book entitled “the Demon in the Freezer--a True Story”, written by the bestselling author, Richard Preston. He has published over 90 articles and holds 50 patents/patent applications. He earned his PhD from the National Key Laboratory of Molecular Virology and Genetic Engineering at the Institute of Virology in the Chinese Academy of Preventive Medicine, China.
HIV and Cancer Vaccines; Viral Genomics and Pathogenesis; Oncolytic Viruses; micro RNAs; Stem Cells
Pranay Khare, PhD has eighteen years of experience in biologic discovery and their development for early stage Phase I, II clinical trials in immunotherapy and gene therapy field. Presently, he is the Director at Cancer Immunotherapy and Gene Therapy cGMP facility of Roger Williams Medical Center, Providence, RI. He is responsible for the genetic modification of T-cells with retroviral vectors expressing chimeric antigen receptor (CAR) for solid tumor clinical trials and bi specific antibody conjugated armed T-cells based clinical trials for solid tumors. His primary role is to direct the clinical scientific collaborative studies on adoptive T cell therapy, CAR-T cell therapy and apart from his research interest he is responsible for modified T cell manufacturing, quality assurance and quality control processes.
His educational background is viral immunology and always fascinated with T cell and their role in disease development and protection. After finishing his Ph.D. in T cell biology in dengue virus disease, he moved to Molecular Oncology Center at Fukuoka University, Japan and then to Molecular Medicine Department at Mayo Clinic, Rochester, MN, USA to apply and develop novel viral vectors and viruses that can target disease specific protein expressed on tumor cells. He develops and has several patents on novel platform technology known as “eukaryotic display technology”. This technology could be used to identify the novel receptors, ligands, biomarkers and antibodies for disease or interested target. Before moving to his current position he was Scientific Director at Neuroscience, Inc where he developed several T cell and cytokine based clinical diagnostic tests for chronic diseases. He has received funding from the National Institute of Health (NIH), Susan G. Komen Breast Cancer Foundation, Leukemia Research Foundation, and other international funding agencies. He also has several prestigious awards from Australia, India, Japan and US foundations and government agencies.
Develop novel therapeutic strategies for solid tumors; Develop novel strategies for adoptive T cell therapy approaches and develop retroviral and lentiviral vectors against tumors which includes the optimal production process development for the chimeric antigen receptor (CAR) expressing T cells (CAR-T); Genetic modification of T-cells with CAR molecules and development of armed T cell (ATC) with bi specific antibody conjugated with T-cells based clinical trials; Basic biology and the role of T cells in the pathogenesis of the dengue virus disease; Optimization protocol for the T cell production process using T cell cytokines that could facilitate a better response for solid tumors using adoptive T cell therapy; Novel target and/or biomarkers in the development of cutaneous T cell lymphoma (CTCL)
Sampath is a Senior Program Manager at Unither Virology LLC where she leads the development of a broad spectrum antiviral program. She received her Ph.D. in Biochemistry in 1999 from University of Delhi, India, where she worked on phage display technology. She completed post-doctoral studies at University of Illinois, Chicago where she studied human papilloma virus molecular biology and at Rice University where she worked on the host take over mechanism of SPO1 bacteriophages. She joined Novartis Institute for Tropical Diseases, Singapore, in early 2003 where she managed a dengue antiviral drug discovery program which included target validation, assay development, high throughput screening (functional enzyme assays, fragment based and in silico screening). In early 2008 she worked on an anti-malarial drug development program at University of Mississippi and Walter Reed Army Institute of Research (WRAIR), USA, where she was involved in development of invitro and invivo models to predict hemolytic toxicity of 8-aminoquinolines. She has served as a subject matter expert for antiviral drug development in the broad spectrum antimicrobials group at the Biomedical Advanced Research and Development Authority (BARDA). She joined Unither Virology LLCin early 2012 and led the IND enabling preclinical studies for a dengue antiviral leading to an IND filing. She has extensive experience in infectious disease drug development and has several publications in peer reviewed journals.
Infectious diseases drug development; antiviral drug development
National Institute of Genetic Engineering and Biotechnology
Developing various bacterial and spore surface displays (including B.subtilis and E.coli) which will finally be applied in vaccine development and bioadsrobent; Expression of industrial enzymes including chymosin, chitinase and so on and use of Genetics Engineering methods to Improve Enzyme activity; Studying Regulation of Bacterial Operons and developing novel expression systems
Olga Latinovic received her M. Sc (2001) and PhD (2006) from Lehigh University, USA, where she was awarded the Sherman Fairchild scholarship for outstanding academic performance. As of 2010, she is an assistant professor working at the Institute of Human Virology (IHV) led by Robert C. Gallo, M.D. at the University of Maryland, School of Medicine in Baltimore, USA. She heads the Laboratory for Imaging Studies of Pathogens and Host Cells Interactions and IHV Imaging facility. Her research focus is on HIV-1 entry and its inhibition into host target cells, particularly focusing on the CCR5 coreceptor which plays a major role in HIV-1 infection and is consequently an attractive target for anti-viral therapy. She wrote the book Micromechanics and Structure of Soft and Biological Materials, as a sole author and published by Verlag Dr. Muller in 2010, and co-authored the book Handbook of Photonics for Biomedical Engineering published by Springer-Verlag in 2013. She lectures Virus Entry course for the grad students at the Department of Microbiology and Immunology at the University of Maryland and she has lectured at various national/international conferences, and is on the Editorial Board of three scientific journals. She is a member of several national and international scientific societies.
HIV-1 entry and its inhibition into host target cells; CCR5 co receptor which plays a major role in HIV-1 infection and is consequently an attractive target for anti-viral therapy
Craig Rayner has more than 15 years of drug development experience. He is CEO of d3 Medicine, a strategic advisory company seeking to develop medicines that matter, against prevailing market failures. His past appointments include leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) Co-Director of Facility for Anti-infective Drug Development and Innovation at Monash University and clinical pharmacology practitioner roles in Australian/US hospitals.
With extensive therapeutic development experience, he has contributed to significant product development efforts for infectious diseases, including the antibiotic Zyvox®, re-vitalising the use of polymyxins against multi-drug resistant pathogens, as the global clinical pharmacology lead for Tamiflu®, as well significant contributions to novel antivirals for HIV, various respiratory viruses and antimalarials.
He holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), and is broadly published in clinical pharmacology and also infectious diseases. he is Chair of Development Committee of Medical Countermeasures Products Australia (MCPA).
The application of clinical pharmacology; Quantitative translational science methods and regulatory science to accelerate development and approval of medicines that matter; Passion for anti-infective drug development; Paediatrics; Neglected diseases; Personalised health care; Policy; Value-focused development
Ekaterina Klimatcheva is a Principal Scientist and a Project Leader at Vaccinex, Inc., a private biotech company in Rochester, NY that has developed a unique method for selecting fully human monoclonal antibodies from antibody libraries expressed in vaccine virus.
Ekaterina has an M.D. from First Moscow State Medical University (Russia) and a Ph.D. in Pharmacology and Toxicology from West Virginia University. Her graduate research focused on deciphering the role of ATP-sensitive K+ channels in proliferation of human breast cancer cells. She conducted her post-doctoral studies at the University of Rochester under guidance of Dr. V. Planelles and Dr. J. Rosenblatt. Her work focused on developing lentiviral vectors for gene therapy of HIV infection. She has been with Vaccinex since 2001, leading projects dedicated to developing human therapeutic antibodies against oncological and autoimmune disorders.
Autoimmunity; Immuno-oncology; Vaccine-based vectors in human antibody selection; Lentiviral vectors in gene therapy
Dr Elna van der Ryst is a physician with extensive postgraduate training in virology and infectious diseases, including a PhD in molecular virology from the UFS in Bloemfontein, South Africa. She has completed a postdoctoral fellowship at the Molecular Virology Unit of the Pasteur Institute in Paris, France.
She joined Pfizer Global Research and Development from a career in academic medicine in 1999. During her time at Pfizer she held a range of clinical leadership roles in the infectious diseases therapeutic area.She played a major role in the development of maraviroc, a novel CCR5 antagonist for the treatment of HIV. Her personal contribution to the discovery and development of maraviroc was recognized when she was named as one of the recipients of the 2010 PhRMA Discoverers award. In 2012 she joined United Therapeutics as VP for Antiviral Clinical Development, and provided clinical leadership to a NIAID funded development program for a novel, broad-spectrum antiviral compound for the treatment of dengue virus infection. She is currently working as an independent consultant.
She has published numerous manuscripts and co-authored several book chapters. She has also given a large number of talks at scientific meetings and is internationally recognized for her expertise in HIV drug development.
HIV, antiviral drug development, antiviral drug resistance
Rachel Roper Ph.D is Associate Professor of Microbiology and Immunology at East Carolina University in the Brody School of Medicine. She received her B. S. from Texas A & M University in 1987, her M.S. in 1990 and her Ph.D. in 1992 from the University of Rochester, School of Medicine and Dentistry where she received the M.A. Hare Research Excellence Award. She received her post-doctoral training in virology with Dr. Bernard Moss at the National Institutes of Health, and was awarded an NIH Fellows Award for Research Excellence. In 1999, she was appointed Director of Immunology and Virology for a British Columbia veterinary vaccine company. In 2001, she became an Adjunct Assistant Professor in Biochemistry & Microbiology at the University of Victoria and also taught at the University of British Columbia. In 2003 she was part of the team that first sequenced and analyzed the SARS virus genome and is an inventor on the issued US patent. She became the Program Director for the British Columbia SARS Accelerated Vaccine Initiative and headed research programs comparing SARS vaccines in both mouse and ferret challenge models. She has received federal funding from Canada and the NIH for work on SARS and poxviruses including monkeypox. She was funded by SERCEB, Southeast Regional Center for Excellence in Biodefense and Emerging Infectious Disease. Her work focuses on viral genomics, immuneregulatory viral virulence factors and vaccine development. She also has a US Patent on the use of a poxvirus gene to improve vaccine safety and efficacy and is a member of the National Academy of Inventors. She has served on international and NIH grant review panels and is an editorial board member for several peer reviewed journals.
Laboratory monitorisation of HIV infected patients, esspecially long term survivors, coinfected with HBV. Resistance mutations of F1 HIV subtype. Diagnose of HSV and HPV infection in general population.
Shenghua Zhou is currently a senior associate scientist and manager at Eli and Edythe Broad CIRM Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine at the University of Southern California. Previously, he was a faculty member and assistant professor at the University of Massachusetts Medical School. He received his Master degree in clinical virology from Tonji Medical University (now Huazhong University of Science & Technology/Tongji Medical College) and PhD degree in viral immunology and molecular virology from Shanghai Medical University (now Fudan University, Shanghai Medical School). He carried out postdoctoral work to study the mechanism of viral pathogenesis at the Medical College of Georgia- Georgia Regents University in Augusta, Georgia. He has over 15 years of experience studying the molecular mechanisms of viral pathogenesis using various virus modelsand has published a series of articles in peer-reviewed journals. He hasextensive experience in the study of both innate and adaptive immune responses against viral pathogens, dissecting the molecular mechanisms of innate immunity using biochemical and molecular biological technologies. In addition, he has extensive experience guiding assay development and optimization for drug screening using high-throughput (luciferase reporter-based platform) and high-content (image-based phenotypic technology)approaches to screen for antiviral, anticancer, and neuroprotective small molecule compounds.
Molecular mechanism of chronic viral infection; Discovery of novel antiviral, anticancer, and neuroprotective therapeutics
Roderick Tang is currently co-founder and CEO of Mesissa Vaccines, Inc. In this role he bridges vaccine design and development, to enable accelerated testing of transformative respiratory viral vaccine candidates in humans. He had previously held positions as senior director of early development at the International AIDS Vaccine Initiative and Principal Scientist at Med Immune. He has also consulted on vaccine development for The World Bank and the Sabin Vaccine Institute. He has a PhD in biophysical chemistry from The John Hopkins University and was a post-doctoral student in virology at University of Colorado, Boulder and Stanford University School of Medicine. His post-doctoral studies were funded in part by The Howard Hughes Medical Institute. He is a member of the American Society for Microbiology and the International Society for Vaccines.
Unmet global health needs; Viral and neglected tropical diseases; Basic understanding of pathogen replication; Pathogenesis and immuno biology with the goal of developing life-saving preventative medicines
UAE University College of Medicine and Health Sciences
United Arab Emirates
Mustafa’s research background and training has been in the area of Molecular Virology. She obtained her doctorate from the University of Massachusetts Medical Center in Worcester, MA USA in 1993 under the tutelage of Professor Harriet L. Robinson, where she studied the replication of the human immunodeficiency virus (HIV), the causative agent of AIDS, in T cells and identified genes that were important in the establishment of long term persistent infections. This was followed by postdoctoral work on how the surface and structural proteins of HIV-1 as well as those of the measles virus could be used as potential immunogens in DNA-based vaccines. She did another post doctoral training at the University of Texas at Austin, TX USA with Professor Jaquelin P. Dudley where she studied the mouse mammary tumor virus (MMTV) that causes both breast cancer and leukemia in mice. Since then, she has continued to work extensively on the fundamentals of retroviral replication using different types of retroviruses including HIV, SIV, FIV, MPMV, and MMTV as model systems.
At present, she is an Assistant Professor at the College of Medicine and Health Sciences (CMHS) of the UAE University.
Regulation of retroviral gene expression, replication, and pathogenesis; Viral etiology of human cancers, especially breast cancer; Novel electrical-based methods of virus detection; Mechanism of virally-induced oncogenesis and virus-host interactions; Identification and characterization of potential anti-cancer and anti-viral plant-based therapies
Shameema Sarker received a doctorate degree in Molecular Biology and Biochemistry from Wesleyan University, followed by post-doctoral studies in Virology at University of Colorado Health Sciences Center. She has been broadly trained in microbiology, molecular biology, and biochemical techniques, with over twenty years of interdisciplinary research and management experience in both academia and industry. She joined Ribomed Biotechnologies, Inc., as a Research Scientist and was involved in a Biosensor Design Project for the Defense Advanced Research Project Agency (DARPA).
For the past 8 years she has also served as an adjunct faculty for the University of Phoenix as well as Subject Matter Expert and Faculty Council member for the College of Humanities and Sciences and recently has been appointed as a Research Associate for the Center for Healthcare Research. Since 2007 she has worked at the Biodesign Institute at Arizona State University as an Associate Research Scientist. Her research involved a multidisciplinary approach to understand how microbial pathogens cause infection and disease. She has also been involved in several spaceflight experiments andin 2014, NASA awardedher special recognition for the Space Tissue Loss payload, Discovery shuttle experiment launched in 2010. As co-PI and co-Investigator on several USDA, NIAID, NASA and NIH-funded grants, she laid the groundwork for many different projects, and have successfully collaborated with prominent researchers, producing several peer-reviewed publications and patents, including her publication in Nature Microbiology.
Shameema is currently working as a Medical Affairs Scientist at Ulthera, Inc., a global medical device company.
Janet L. Lathey is currently a consultant specializing in Bioassay development, validation and standardization.As Director of Immunology and Assay Validation at Emergent BioSolutions in Gaithersburg, MD, her primary work areas were Toxin Neutralization assays, ELISA, and ELIspot for Anthrax vaccine evaluations. Previously, she was Associate Deputy Director for Global Clinical Immunology at Sanofi Pasteur, Swiftwater, PA. As a Project Representative she was involved with standardizing assays for influenza clinical trials and efficacy studies. Before moving to Sanofi Pasteur, Janet was Director of Virology and Immunology at SeraCare in Gaithersburg, MD. Here she was responsible for developing an ELIspot kit for market and setting up proficiency testing using ELIspot for HIV and Cancer programs. Previous to SeraCare she was a clinical immunology group leader at ZYCOS, Lexington, MA. There she was involved in testing a therapeutic vaccine for HPV.
As part of her academic career before moving to industry she was co- director of the Retrovirology Laboratory at the University of California, San Diego. She was involved in the immunological and virological evaluations of anti-retroviral clinical trials for treatment of HIV.
Evaluation of vaccine production and immunogenicity, and assay performance.Viruses worked with include HIV, Influenza, HPV, HSV, and CMV.
Pirouz Daftarian completed his PhD studies at the Department of Microbiology, Faculty of Medicine, University of Ottawa where he studies the immunopathogenesis of HIV infection with a focus on the role of cytokines and co-stimulatory molecules. Ever since, he has been conducting R&D studies, in both industry and academia, on design and test of adjuvant viral-based, peptide-based, and DNA based vaccines and immunotherapeutic for infectious diseases and cancer, in particular for HIV, CMV, HPV, breast cancer, melanoma, and leis mania. He has over fourteen years of experience in areas of immunotherapeutic and immune-monitoring, in vivo / in vitro models for drug/ vaccine efficacy assessment, bioanalytical, and characterization studies including stability and safety of therapeutics. More recently, he uses nanotechnology and modern immunology to further enhance the robustness of therapeutics. These studies have resulted in the development of nanocarriers for drug or vaccine delivery that are both targeted and adjuvanted. He is the principal inventor of 8 patents in the area of vaccine, immunomonitoring and targeted cell therapies. He has acted as consultants for pharmaceutical and biotech companies, NIH/ NCI intramural expert reviewer for a vaccine proposal, Guide point Global, Thomson Reuters and Thomson Reuters Expert Witness. He has published more than 30 scientific articles or book chapters in peer reviewed journals or scientific books. Currently, he is an assistant professor at Miller School of Medicine, is a co-founder of Nanovax Company. Prior to UM, he has served at industry as Head Scientist at Imvaccine Inc., and Director of Biological Modifier Laboratory, in the University of Miami, the University of Dalhousie, the Vaccine Laboratory of the City of Hope National Medical Center and at UBC.
Dr. Singh was awarded Doctorate in Philosophy (PhD) in Biophysics from University of Delhi, India in 1997. His postdoctoral training included Alexander von Humboldt Fellowship at Institute of Hematopathology, University of Kiel, Germany, and at The Scripps Reaserch Institute, La Jolla, CA and University of California San Diego (UCSD). He became an Assistant Professor in 2009 and was promoted to Associate Professor in 2013 at Division of Infectious Diseases, Department of Pediatrics, and UCSD. He has published more than 40 peer reviewed publications on fluorescent methods to detect and kinetically characterize nucleic acids, ribozyme kinetics, role of telomerase in aging and cancer, host genetic factors in HIV-1 transmission from mother-to-children, risk of HIV infection and progression to AIDS and neuro AIDS in children and adults.
Innate/adaptive immunity interface in central nervous system infections and neurodegeneration. Host genetic variations in susceptibility and disease progression of HIV infection to AIDS and neuroAIDS. Pharmacogenomics of drug responses and drug toxicity in treatment of infectious diseases. Rapid detection and diagnosis of infectious agents.
Role of Innate defense in cancer and against microbial infection; To understand the contribution of innate immunity in therapeutic resistance and gain of survival function in cancer cells; To develop effective oncolytic virotherapy against otherwise intractable late-stage cancers by manipulating antiviral innate immune response in cancer cells; To develop readout for high throughput screening of chemical libraries using certain molecular target in cancer and viral infections.
Ala Eddin Al Moustafa
MEACR/Syrian Research Cancer Centre/McGill U